Testing for a rare mutation in lung cancer cases could reveal option for treatment with Crizotinib
ROS1 is a rare mutation in lung cancer (1-2% of patients) and those with ROS1-fusion genes are eligible for treatment with the drug Crizotinib.
Published research literature was analysed to find patient characteristics of ROS1-positive lung cancer cases. Findings showed that the mean age of patients was 57 years, 63.6% were female and that ROS1 occurs in Non-small cell lung cancer (NSCLC) cases with EGFR mutations.
The authors suggest that mutation testing of ROS1 in patients with EGFR mutations and a squamous or small cell histology compound could reveal treatment with Crizotinib for those patients.
Read the article abstract in European Respiratory Journal, Vol 48 (60), 2016